People with MASLD are at increased risk of developing hepatic decompensation and hepatocellular carcinoma, and are also at increased risk of type 2 diabetes mellitus, cardiovascular disease, and chronic kidney disease.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide. People with MASLD can progress to cirrhosis and have an increased risk of developing hepatic decompensation and hepatocellular carcinoma. People with MASLD are also at increased risk of type 2 diabe...
S. Schuth, K. Kantartzis, A. Birkenfeld et al.· Diabetes & Metabolism Jo...· 0 citations
Raising awareness of MASLD among the general public and at-risk populations, unifying existing guidelines for cardiometabolic diseases, and the development of regional and global strategies to combat MASLD are essential to tackle the cardiometabolic pandemic.
I. Gaisin, E. Kochurov, E. А. Loshkarev et al.· Perm Medical Journal· 0 citations
This study compared metabolic dysfunction‐associated steatotic liver disease (MASLD) in individuals with Werner syndrome (WS) and individuals with insulin‐resistant type 2 diabetes (T2D). It also examined the association with imaging findings of MASLD in individuals with WS, clarified the characteristics of MASLD that...
Makoto Miyabayashi, M. Koshizaka, M. Shoji et al.· Geriatrics & Gerontology Int...· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence worldwide. Pathogenesis of MASLD has been considerably heterogenous. Increased hepatic de novo lipogenesis, adipose tissue dysfunction, genetic predisposition, epigenetic mechanism, and other related factors have been associate...
Kyung-Soo Kim, S. Lim, Cheol-Young Park· EXCLI Journal : Experimental...· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently considered one of the most common chronic liver diseases and is closely associated with the increasing prevalence of obesity, insulin resistance, type 2 diabetes mellitus, and other cardiometabolic disorders. Unlike the previously used term “...
O. B. Najmitdinov, S. Abdullaev· Journal of modern medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.